Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biocon

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

Roche Basel Switzerland

Roche files Tecentriq/Avastin combo in liver cancer

First treatment in over a decade to improve overall survival

- PMLiVE

EU grants conditional approval to Roche’s lymphoma drug Polivy

Drug demonstrated a 40% complete response rate in trial

Roche Basel Switzerland

Roche and Illumina partner on genomics for cancer diagnostics

Will leverage genomics system to match optimal cancer treatment

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

- PMLiVE

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Sets stage for lower-cost competition to big-selling drug

Roche Basel Switzerland

Roche pays $1.15bn for Sarepta’s Duchenne gene therapy

Pens another gene therapy deal following takeover of Spark Therapeutics

Roche Basel Switzerland

Roche to close $4.3bn Spark deal after FTC clearance

Comes on the heels of CMA green light

- PMLiVE

UK’s CMA clears Roche’s $4.3bn takeover of Spark

Roche first announced deal in February

- PMLiVE

Roche’s Tecentriq combo scores in first-line melanoma

Plans to file treatment with health authorities on strength of data

- PMLiVE

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved

- PMLiVE

Mylan, Biocon’s Herceptin biosimilar launched in US

Bad news for Roche as its ageing blockbuster continues to lose ground

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links